Literature DB >> 23731635

Osteoclasts in RA: diverse origins and functions.

Benoit Le Goff1, Jean-Marie Berthelot, Yves Maugars, Dominique Heymann.   

Abstract

Osteoclasts were recognized in the late 1990s as the cells responsible for generalized and focal bone loss in rheumatoid arthritis (RA). Concepts about osteoclast biology have changed radically based on recent evidence of considerable diversity in both the origins and the functions of osteoclasts. In addition, the role for osteoclasts is not confined to bone resorption but may also include active contributions to inflammatory and autoimmune responses. Thus, in RA, osteoclast progenitors may arise from both circulating cells and cells developed within the rheumatoid synovium or subchondral bone. Within the inflamed synovium, osteoclasts are activated by factors such as cytokines, immune complexes, or activators of the toll-like receptors, which are not found in healthy bone tissue. Finally, recent data suggest that osteoclasts may be capable of antigen presentation to T cells via major histocompatibility complex class I and class II molecules. Confirmation of this suggestion by future studies would indicate that osteoclasts might be involved not only in bone resorption, but also in autoimmune responses and antigen presentation. These data highlight the considerable complexity of interactions between bone tissue and the immune system. Research into these interactions may identify new targets for treatments against the bone abnormalities associated with chronic inflammatory disease.
Copyright © 2013 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  B lymphocyte; Immune complexes; Osteoclasts; Rheumatoid arthritis; T lymphocyte; Toll-like receptors

Mesh:

Year:  2013        PMID: 23731635     DOI: 10.1016/j.jbspin.2013.04.002

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  10 in total

1.  Shared epitope-antagonistic ligands: a new therapeutic strategy in mice with erosive arthritis.

Authors:  Song Ling; Ying Liu; Jiaqi Fu; Alessandro Colletta; Chaim Gilon; Joseph Holoshitz
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

2.  Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis.

Authors:  M Ikić Matijašević; D Flegar; N Kovačić; V Katavić; T Kelava; A Šućur; S Ivčević; H Cvija; E Lazić Mosler; I Kalajzić; A Marušić; D Grčević
Journal:  Clin Exp Immunol       Date:  2016-10-18       Impact factor: 4.330

Review 3.  Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis.

Authors:  Alan Sućur; Vedran Katavić; Tomislav Kelava; Zrinka Jajić; Natasa Kovačić; Danka Grčević
Journal:  Int Orthop       Date:  2014-06-10       Impact factor: 3.075

4.  Hematopoietic or Osteoclast-Specific Deletion of Syk Leads to Increased Bone Mass in Experimental Mice.

Authors:  Dániel Csete; Edina Simon; Ahmad Alatshan; Petra Aradi; Csaba Dobó-Nagy; Zoltán Jakus; Szilvia Benkő; Dávid S Győri; Attila Mócsai
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

Review 5.  Multinucleated Giant Cells: Current Insights in Phenotype, Biological Activities, and Mechanism of Formation.

Authors:  Kourosh Ahmadzadeh; Margot Vanoppen; Carlos D Rose; Patrick Matthys; Carine Helena Wouters
Journal:  Front Cell Dev Biol       Date:  2022-04-11

6.  ROCK inhibition with Y-27632 reduces joint inflammation and damage in serum-induced arthritis model and decreases in vitro osteoclastogenesis in patients with early arthritis.

Authors:  Angela Rodríguez-Trillo; Carmen Pena; Samuel García; Eva Pérez-Pampín; Marina Rodríguez-López; Antonio Mera-Varela; Antonio González; Carmen Conde
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

7.  Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 β -induced RANKL, OPG, TNF α , and IL-6 expression in human rheumatoid synoviocyte MH7A.

Authors:  Xiaoke Feng; Chengyin Lv; Fang Wang; Ke Gan; Miaojia Zhang; Wenfeng Tan
Journal:  Clin Dev Immunol       Date:  2013-11-18

8.  Graphene-Based MicroRNA Transfection Blocks Preosteoclast Fusion to Increase Bone Formation and Vascularization.

Authors:  Ce Dou; Ning Ding; Fei Luo; Tianyong Hou; Zhen Cao; Yun Bai; Chuan Liu; Jianzhong Xu; Shiwu Dong
Journal:  Adv Sci (Weinh)       Date:  2017-12-04       Impact factor: 16.806

9.  Regulatory effect of anti-gp130 functional mAb on IL-6 mediated RANKL and Wnt5a expression through JAK-STAT3 signaling pathway in FLS.

Authors:  Ping Miao; Xiao Wei Zhou; Ping Wang; Rong Zhao; Ninan Chen; Chao Ying Hu; Xue Hua Chen; Liu Qian; Qi Wen Yu; Ji Ying Zhang; Rong Xu; Dong Yi He; Lian Bo Xiao; Pu Li; Mason Lu; Dong Qing Zhang
Journal:  Oncotarget       Date:  2018-01-04

10.  Bone-targeted pH-responsive cerium nanoparticles for anabolic therapy in osteoporosis.

Authors:  Ce Dou; Jianmei Li; Jian He; Fei Luo; Tao Yu; Qijie Dai; Yueqi Chen; Jianzhong Xu; Xiaochao Yang; Shiwu Dong
Journal:  Bioact Mater       Date:  2021-05-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.